HealthCare Sector trading lower by -0.14% General Commentary: Novogen (NVGN) is trading higher by over 100% this morning. The move appears to be related to positive results for the company's lead experimental drug CS-6. A study, conducted by Mazor Oncology, was designed to test the ability of CS-6 to kill ovarian cancer stem cells. Cancer stem cells have been identified in a range of cancers including gut, skin, ovarian and brain cancers and leukaemia. Cancer stem cells are almost completely resistant to radiotherapy and standard anti-cancer drugs. Although representing less than about 1% of all cells present in these cancers, they are thought to be the cause of cancer relapse following radiotherapy and chemotherapy where the bulk of the tumour is replaced with new highly- resistant cells derived from the cancer stem cells. In laboratory tests conducted since Novogen acquired its new Triaxial drug technology, "CS-6 has proved highly effective at stopping the growth of these cancer stem cells, eventually causing them to die."

Briefing.com is the leading Internet provider of live market analysis for U.S. Stock, U.S. Bond, and world FX market participants.

Read more Story Stocks articles